Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)

被引：0
|
作者：
Pemmaraju, Naveen [1 ]
Kantarjian, Hagop [2 ]
Shan, Jianqin [2 ]
Jabbour, Elias [2 ]
Quintas-Cardama, Alfonso
Verstovsek, Srdan
Ravandi, Farhad
Wierda, William G. [2 ]
O'Brien, Susan [2 ]
Cortes, Jorge E. [2 ]
机构：
[1] MD Anderson, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：527 / 528
页数：2
相关论文
共 50 条
  • [31] Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML).
    Chen, Yaozhu J.
    Huang, Hui
    Divino, Victoria
    Pokras, Shibani
    Hallinan, Shawn
    Munakata, Julie
    Taylor, Catherine
    McGarry, Lisa
    Ng, Daniel
    Nieset, Christopher
    Knopf, Kevin B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)
    Nodzon, Lisa
    Tinsley-Vance, Sara
    BLOOD, 2017, 130
  • [33] APPLICATION OF THE EUTOS SCORE IN A SERIES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP) TREATED WITH TYROSIN KINASE INHIBITORS (TKI)
    Xicoy, B.
    Boque, C.
    Fernandez, C.
    Vallansot, R.
    Cortes, M.
    Ortin, X.
    Rodriguez, L.
    Plensa, E.
    Buch, J.
    Marce, S.
    Garcia, O.
    Velez, P.
    Abenoza, L.
    Miguel, L.
    de Sevilla, A.
    Grau, J.
    Estrada, N.
    Ribera, J.
    HAEMATOLOGICA, 2013, 98 : 552 - 552
  • [34] EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA(CML) IN THE ERA OF TYROSINE KINASE INHIBITORS (TKIS)
    Autore, F.
    Ora, F.
    Chiusolo, P.
    Laurenti, I.
    Giammarco, S.
    Vannata, B.
    Ausoni, G.
    Metafuni, E.
    Innocenti, I.
    Leone, G.
    Sica, S.
    HAEMATOLOGICA, 2013, 98 : 560 - 561
  • [35] Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)
    Lagana, Alessandro
    Scalzulli, Emilia
    Bisegna, Maria Laura
    Ielo, Claudia
    Martelli, Maurizio
    Breccia, Massimo
    EXPERT REVIEW OF HEMATOLOGY, 2025, 18 (01) : 65 - 79
  • [36] Survival outcomes for patients (Pts) with chronic myeloid leukemia (CML) with clonal evolution (CE) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure
    Verma, Dushyant
    Kantarjian, Hagop
    Estrov, Zeev
    Garcia-Mancro, Guillermo
    Koller, Charles
    Borthakur, Gautam
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 866A - 867A
  • [37] Memory Impairment in Chronic phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Tanaka, Maria F.
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1610 - 1611
  • [38] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [39] Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors
    Sakurai, Masatoshi
    Mori, Takehiko
    Karigane, Daiki
    Tozawa, Keiichi
    Matsuki, Eri
    Shimizu, Takayuki
    Yokoyama, Kenji
    Nakajima, Hideaki
    Kanda, Yoshinobu
    Okamoto, Shinichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (03) : 342 - 348
  • [40] Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors
    Masatoshi Sakurai
    Takehiko Mori
    Daiki Karigane
    Keiichi Tozawa
    Eri Matsuki
    Takayuki Shimizu
    Kenji Yokoyama
    Hideaki Nakajima
    Yoshinobu Kanda
    Shinichiro Okamoto
    International Journal of Hematology, 2015, 102 : 342 - 348
12345